Adimune Platform Programs
Type 1 Diabetes, Vitiligo, Transplant Rejection
Preclinical/ClinicalActive
Key Facts
Indication
Type 1 Diabetes, Vitiligo, Transplant Rejection
Phase
Preclinical/Clinical
Status
Active
Company
About Aditxt
Aditxt is a clinical-stage biotech focused on immune system reprogramming through its AditxtScore and Adimune platforms. The company aims to commercialize tools for immune monitoring and develop therapies for autoimmune disorders and transplant rejection. With a pipeline in preclinical and early clinical stages, Aditxt is a high-risk, high-potential venture in the immunology space. Its financial position and market valuation reflect the speculative nature of its early-stage technology.
View full company profile